HALO vs NBIX: stock comparison and AI forecast
Halozyme Therapeutics, Inc. (HALO) and Neurocrine Biosciences Inc (NBIX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
HALO Halozyme Therapeutics, Inc.
- Price
- $130.91 +105.6% · 6M
- Market Cap
- $14.86B
- P/E Ratio
- 30.1x
- Size
- large-cap
- AI Forecast
- NO CURRENT FORECAST
NBIX Neurocrine Biosciences Inc
- Price
- $146.38 +11.2% · 6M
- Market Cap
- $14.88B
- P/E Ratio
- 21.2x
- Size
- large-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- HALO and NBIX have similar market capitalizations ($14.86B and $14.88B).
- NBIX trades at 21.2 times trailing earnings, HALO at 30.1 times.
- Over the last six months HALO returned +105.6% and NBIX +11.2%.
- HALO turns 24.9% of its revenue into net income, against 20.9% for NBIX.
- HALO carries 16.96 times debt per unit of equity, against 0.45 times for NBIX.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | HALO | NBIX |
|---|---|---|
| Market Cap | $14.86B | $14.88B |
| P/E Ratio | 30.09x | 21.18x |
| P/B Ratio | 103.51x | 4.03x |
| EPS | $4.35 | $6.91 |
| Book Value/Share | $1.26 | $36.34 |
| Revenue/Share | $14.66 | $33.19 |
| FCF/Share | $7.10 | $8.56 |
Profitability & Margins
| Metric | HALO | NBIX |
|---|---|---|
| ROE | 288.1% | 19.1% |
| ROA | 16.1% | 13.2% |
| ROIC | 26.7% | 17.7% |
| Gross Margin | 82.4% | 98.4% |
| Operating Margin | 35.9% | 23.6% |
| Net Margin | 24.9% | 20.9% |
| EBT Margin | 35.1% | 27.9% |
| Tax Rate | 29.1% | 25.0% |
Financial Health
| Metric | HALO | NBIX |
|---|---|---|
| Current Ratio | 2.71x | 1.87x |
| Quick Ratio | 2.31x | 1.75x |
| D/E Ratio | 16.96x | 0.45x |
| Financial Leverage | 17.96x | 1.45x |
| Interest Coverage | – | 56.1x |
| Working Capital | $589M | $763M |
Cash Flow
| Metric | HALO | NBIX |
|---|---|---|
| Operating Cash Flow | $819M | $898M |
| Free Cash Flow | $806M | $870M |
| Capital Spending | -$12M | -$28M |
| OCF Growth YoY | 49.4% | 58.3% |
| FCF Growth YoY | 49.1% | 64.6% |
| FCF/Sales | 48.5% | 25.8% |
| CapEx/Sales | 0.7% | 0.8% |
Operational Efficiency
| Metric | HALO | NBIX |
|---|---|---|
| Asset Turnover | 0.65x | 0.63x |
| Receivables Turnover | 3.7x | 3.8x |
| Inventory Turnover | 2.1x | 0.5x |
| Fixed Assets Turnover | 33.4x | 37.3x |
| Days Sales Outstanding | 99 days | 96 days |
| Days Inventory | 171 days | 694 days |
| Payables Period | 29 days | 946 days |
| Cash Conversion Cycle | 241 days | -156 days |
Income Statement
| Metric | HALO | NBIX |
|---|---|---|
| Total Revenue | $1.66B | $3.37B |
| Operating Income | $597M | $795M |
| Net Income | $414M | $706M |
| R&D Expense | $102M | $1.13B |
| SG&A Expense | $238M | $1.35B |
| Cost of Goods Sold | $292M | $55M |
Dividend & Shareholder Information
| Metric | HALO | NBIX |
|---|---|---|
| Shares Outstanding | 114M | 102M |
| Net Income Growth | -25.8% | 102.6% |
| EPS Growth | 7.7% | 85.8% |
HALO vs NBIX: stock comparison and AI forecast
Which is bigger, HALO or NBIX?
HALO and NBIX have similar market capitalizations ($14.86B and $14.88B).
Which is cheaper on earnings, HALO or NBIX?
NBIX trades at 21.2 times trailing earnings, HALO at 30.1 times.
Which stock performed better over the last six months, HALO or NBIX?
Over the last six months HALO returned +105.6% and NBIX +11.2%.
Which one does Intratio's AI model rank higher, HALO or NBIX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.